Prognostic factors of outcome by multivariate analysis
| . | . | ORR . | ORR 95% CI . |
|---|---|---|---|
| Overall survival | |||
| ECOG | ≥ 2 vs < 2 | 2.05 | 1.28-3.28 |
| Nodal sites | > 4 vs ≤ 4 | 1.18 | 1.02-1.36 |
| Event-free survival | |||
| ECOG | ≥ 2 vs < 2 | 1.61 | 1.13-2.27 |
| Nodal sites | > 4 vs ≤ 4 | 1.21 | 1.11-1.33 |
| Progression-free survival | |||
| ECOG | ≥ 2 vs < 2 | 1.61 | 1.12-2.31 |
| Nodal sites | > 4 vs ≤ 4 | 1.19 | 1.08-0.30 |
| ITT group | CHVP vs HDT | 1.82 | 1.14-2.91 |
| . | . | ORR . | ORR 95% CI . |
|---|---|---|---|
| Overall survival | |||
| ECOG | ≥ 2 vs < 2 | 2.05 | 1.28-3.28 |
| Nodal sites | > 4 vs ≤ 4 | 1.18 | 1.02-1.36 |
| Event-free survival | |||
| ECOG | ≥ 2 vs < 2 | 1.61 | 1.13-2.27 |
| Nodal sites | > 4 vs ≤ 4 | 1.21 | 1.11-1.33 |
| Progression-free survival | |||
| ECOG | ≥ 2 vs < 2 | 1.61 | 1.12-2.31 |
| Nodal sites | > 4 vs ≤ 4 | 1.19 | 1.08-0.30 |
| ITT group | CHVP vs HDT | 1.82 | 1.14-2.91 |
CI indicates confidence interval; ECOG, ECOG performance status; and ITT, intention-to-treat.